In HCC, it inhibits the central Raf/MEK/ERK proliferative axis and the pro‐inflammatory PKC/NF‐κB pathway, the latter by preventing NF‐κB p65 nuclear translocation [51]. Here, NFKB1 is linked to hepatocellular carcinoma.